Therapeutic Thursday: The Deals Are Outrunning the Data in Oncology's Next Wave
Two qualify as first-in-class among 2032's ten biggest oncology bets. So why is big pharma paying nine figures for assets that haven't read out?
Capsul Desk
7 min read
members